PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Cenobamate→

Cenobamate PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
913088-80-9
Molecular formula
C10H10ClN5O2
Molecular weight
267.67 g/mol
Drug class
Antiseizure medicinevoltage-gated sodium-channel modulator and positive allosteric GABAA receptor modulator
Mechanism of action
Reduces repetitive neuronal firing by inhibiting persistent sodium currents and can enhance inhibitory signalling through positive allosteric modulation of GABAA receptors. The relative contribution of these actions to clinical antiseizure effects is not fully defined.
Indications / reported uses
  • Treatment of partial-onset (focal) seizures in adults; use requires gradual dose titration because of serious hypersensitivity and other safety risks

Sources: US DailyMed — XCOPRI (cenobamate) · FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Cenobamate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Cenobamate Permitted Daily Exposure (PDE) report (the Cenobamate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Cenobamate Occupational Exposure Limit (OEL) report (the Cenobamate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.